Finn Schultz Larsen, Keld Urup Jacobsen
DOI: 10.2340/0001555592128129

In a double-blind cross-over trial, 23 adults with atopic dermatitis were treatrd systemically during two 6-week periods wilh a new anti-allergic chromone compound (FPL 57787) 18 mg four times a day or matched placebo in randomized order. Twenty patients completed the study: 11 preferred the active period, 9 prefcrred the placebo period. There were no statistically significant differences for any parameter. Four of the patients had drug-related dyspepsia. No laboratory side effects were noted.